EN DE
Watch Beijing Luzhu Biotechnology Co for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Beijing Luzhu Biotechnology Co (2480) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Beijing Luzhu Biotechnology Co stock HK$11.00, price HK$15.35, that is 28.3% below the price, quality 52 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China

BL Beijing Luzhu Biotechnology Co logo Thin data Nov 10, 2026

Beijing Luzhu Biotechnology Co

2480 · HK
Expensive, in a downtrend

Our calculation puts a fair price 28% below what the stock costs today.

Low debt
Ranks above peers (6/8)
Quality 52/100
Fair value HK$11.00 · Overvalued
Negative free cash flow
Narrow moat 6/100 · thin data
Thin data
Estimate⚠ Thinly traded
Watch Beijing Luzhu Biotechnology Co for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$41.20 HK$12.00 Fair Value HK$11.00 May 2023 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

42‑month range HK$12.00 – HK$41.20 · fair‑value band HK$8.25 – HK$13.75 · the HK$15.35 price screens above the HK$11.00 fair value. As of Nov 10, 2026.

Follow Beijing Luzhu Biotechnology Co in your weekly email

Every Wednesday you see whether Beijing Luzhu Biotechnology Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Beijing Luzhu Biotechnology Co., Ltd., a biotechnology company, develops human vaccines and therapeutic biologics to prevent and control infectious diseases, and to treat cancer and autoimmune diseases in Mainland China.

Show moreShow less

The company is developing LZ901, a recombinant herpes zoster vaccine for which a biologics license application (BLA) has been submitted; K3, a recombinant human anti-tumor necrosis factor-alpha monoclonal antibody injection that has completed a Phase 1 clinical trial for the treatment of autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis; and K193, a bispecific antibody injection in a Phase 1 clinical trial for the treatment of B cell leukemia and lymphoma.

Its preclinical-stage product candidates comprise a recombinant varicella vaccine for the prevention of varicella in children; a recombinant syncytial virus (RSV) vaccine for RSV-induced lower respiratory tract disease; a recombinant HSV-1 vaccine that targets oral herpes or cold sores; a recombinant HSV-2 vaccine that targets genital herpes; K333, a bispecific antibody injection product for the treatment of myeloid leukemia; and K1932, a bispecific antibody to treat b cell lymphoma.

In addition, the company offers immunoreagents, such as Group A meningococcal polysaccharide IgG, Group C meningococcal polysaccharide IgG, Group Y meningococcal polysaccharide IgG, Group W135 meningococcal polysaccharide IgG, and Haemophilus influenzae Type B polysaccharide IgG antibody detection kits; varicella-zoster virus antibody ELISA testing kits; and varicella-zoster virus antigen slides.

Beijing Luzhu Biotechnology Co., Ltd. was incorporated in 2001 and is headquartered in Beijing, China.

Stock analysis

Beijing Luzhu Biotechnology Co (2480) currently trades at HK$15.35, while our estimate is HK$11.00, 28% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: HK$8.25 (bear) to HK$13.75 (bull), the price of HK$15.35 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.

Beijing Luzhu Biotechnology Co reported revenue of 0 CNY in FY2025 versus 0 CNY in FY2021. Reported net income was −150M CNY in FY2025.

Key figures

Market cap HK$3.1B (≈ $389M) Small · Return on equity −20.1% · Return on assets (EBIT) −26.5% (5-year average) · Free cash flow −HK$190M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 41% below its 52-week high and 28% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −28%, 2480 screens richer than that median.

Fair Value

Bear HK$8.25 Fair Value HK$11.00 Bull HK$13.75
Price HK$15.35 · Downside -28.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 52/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 58
Are margins and returns getting better?
Cashflow 24
Do the profits arrive as real cash?
Financial strength 77
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 63
How calm the share price moves, does not count
Price momentum 25
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 14
Distance to the 52-week high, does not count
New shares 88
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

2480 screens overvalued: fair value 28% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Beijing Luzhu Biotechnology Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 5/7 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 52 · Top 25%
Fair Value upside −28.3% · Below median
Profitability
Return on assets −14.5% · Above median
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median
Balance sheet
Debt / equity 0.34× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.59× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)83 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 2480
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 2480
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 2480
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 2480
argenx SE ARGX $971.55 $908.40 −7% vs 2480
CSL Limited CSL A$201.68 A$181.40 −10% vs 2480
Moderna, Inc MRNA $250.83 $158.70 −37% vs 2480
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 2480
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 2480
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 2480

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Beijing Luzhu Biotechnology Co: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Beijing Luzhu Biotechnology Co Fair Value". https://www.fairvalue-calculator.com/stock/2480.HK

Frequently asked questions

Is Beijing Luzhu Biotechnology Co (2480) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is HK$11.00 versus a price of HK$15.35, about 28% lower (overvalued).
What is the fair value of 2480?
Our estimate for Beijing Luzhu Biotechnology Co is HK$11.00 (as of Nov 10, 2026), built from audited fundamentals. The current price: HK$15.35.
What is the quality score of 2480?
Beijing Luzhu Biotechnology Co has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Beijing Luzhu Biotechnology Co (2480)?
Our calculated price target is the estimate of HK$11.00 (as of Nov 10, 2026). Cautious scenario HK$8.25, optimistic scenario HK$13.75. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Beijing Luzhu Biotechnology Co stock forecast for 2026?
Our estimate puts fair value at HK$11.00, about 28% lower versus a price of HK$15.35 (overvalued). Cautious scenario HK$8.25, optimistic scenario HK$13.75. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Beijing Luzhu Biotechnology Co (2480)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Beijing Luzhu Biotechnology Co it is HK$11.00 per share (as of Nov 10, 2026), against a price of HK$15.35.
Is Beijing Luzhu Biotechnology Co stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 2480 trades above its calculated fair value: price HK$15.35, fair value HK$11.00, a gap of about −28% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2480?
No. The price is what the market pays today (HK$15.35); the fair value is what the company's own numbers justify (HK$11.00). For Beijing Luzhu Biotechnology Co the two are HK$4.35 per share apart. That gap is exactly why we show both numbers side by side.
How much is Beijing Luzhu Biotechnology Co worth?
The market values Beijing Luzhu Biotechnology Co at about HK$3.1B (market capitalisation, as of Nov 10, 2026). Per share that is HK$15.35; our models calculate a fair value of HK$11.00 per share.
What do the bullish and bearish scenarios say about 2480?
Our models span a range for Beijing Luzhu Biotechnology Co: cautious scenario HK$8.25, base HK$11.00, optimistic HK$13.75 per share (as of Nov 10, 2026, price HK$15.35). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Beijing Luzhu Biotechnology Co (2480)?
Balance-sheet figures for Beijing Luzhu Biotechnology Co (as of Nov 10, 2026): return on equity −20.1%, debt of 0.34 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is 2480 from its 52-week high?
Beijing Luzhu Biotechnology Co trades at HK$15.35, about 41% below its 52-week high of HK$25.98 and 28% above the low of HK$12.00 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of HK$11.00 is for.
Which stocks are comparable to Beijing Luzhu Biotechnology Co?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Beijing Luzhu Biotechnology Co stock attractive at the current price?
The data as of Nov 10, 2026: price HK$15.35, calculated fair value HK$11.00 (−28%), Quality Score 52/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Beijing Luzhu Biotechnology Co itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Beijing Luzhu Biotechnology Co (2480)?
The closing price on Nov 10, 2026 was HK$15.35. Our estimate is HK$11.00, about 28% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Beijing Luzhu Biotechnology Co right now?
The price sits above even our optimistic bull case (HK$13.75). The favourable scenario is already priced in. Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Beijing Luzhu Biotechnology Co

How large is the market capitalisation of Beijing Luzhu Biotechnology Co (2480)?
The market capitalisation of Beijing Luzhu Biotechnology Co is HK$3.1B (≈ $389M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the return on equity of Beijing Luzhu Biotechnology Co (2480)?
The return on equity (ROE) of Beijing Luzhu Biotechnology Co is −20.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Beijing Luzhu Biotechnology Co (2480)?
On an EBIT basis the return on assets of Beijing Luzhu Biotechnology Co is −26.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Beijing Luzhu Biotechnology Co (2480) generate?
The free cash flow of Beijing Luzhu Biotechnology Co is −HK$190M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Beijing Luzhu Biotechnology Co in the live analysis

One click puts Beijing Luzhu Biotechnology Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.